RMS
Showing 1 - 25 of 544
Early Versus Late Ofatumumab Use in Austrian RMS-Patients Over 2
Not yet recruiting
- Relapsing Multiple Sclerosis
- Ofatumumab
- (no location specified)
Mar 17, 2023
PET/MR for Characterization of Renal Masses (RMs)
Recruiting
- Renal Tumor
- +2 more
- 2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging
-
Dallas, TexasUniversity of Texas Southwestern Medical Center
Oct 5, 2023
Multiple Sclerosis Trial (Dimethyl fumarate)
Not yet recruiting
- Multiple Sclerosis
- Dimethyl fumarate
- (no location specified)
Dec 12, 2022
Relapsing Multiple Sclerosis (RMS) Trial in United States (Ublituximab, Teriflunomide, Oral Placebo)
Completed
- Relapsing Multiple Sclerosis (RMS)
- Ublituximab
- +3 more
-
Phoenix, Arizona
- +12 more
Nov 11, 2021
Relapsing Multiple Sclerosis (RMS) Trial in United States (Ublituximab, Teriflunomide, Oral Placebo)
Completed
- Relapsing Multiple Sclerosis (RMS)
- Ublituximab
- +3 more
-
Carlsbad, California
- +13 more
Nov 5, 2021
Benign Paroxysmal Positional Vertigo Trial in Istanbul (Automated vertigo repositioning chair, Canalith Reposition Maneuver)
Completed
- Benign Paroxysmal Positional Vertigo
- Automated vertigo repositioning chair
- Canalith Reposition Maneuver
-
Istanbul, Sultangazi, TurkeyHaseki Sultangazi Training and Research Hospital
Apr 23, 2022
FFPE Samples From Younger Patients With Rhabdomyosarcoma
Completed
- Alveolar Childhood Rhabdomyosarcoma
- +2 more
-
Jinan, Shandong, ChinaJinan central hospital affiliated to Shandong First Medical Univ
Sep 10, 2023
Rhabdomyosarcoma, Child Trial (Realgar-Indigo Naturalis Formulation, Radiotherapy)
Not yet recruiting
- Rhabdomyosarcoma, Child
- Realgar-Indigo Naturalis Formulation
- Radiotherapy
- (no location specified)
Jan 31, 2023
Relapsing Remitting Multiple Sclerosis Trial in United States (Ublituximab)
Active, not recruiting
- Relapsing Remitting Multiple Sclerosis
- Ublituximab
-
Pasadena, California
- +7 more
Aug 19, 2022
Relapsing Multiple Sclerosis (RMS) Trial in China (Fingolimod 0.5mg)
Recruiting
- Relapsing Multiple Sclerosis (RMS)
- Fingolimod 0.5mg
-
Beijing, Beijing, China
- +12 more
Feb 3, 2022
RMS Patients on Ofatumumab or Ocrelizumab inReal-World Setting
Recruiting
- Relapsing Multiple Sclerosis
- Ofatumumab
- Ocrelizumab
-
Dubai, United Arab EmiratesNovartis Investigative Site
Aug 8, 2022
Multiple Sclerosis Trial in Los Angeles (Blood draw for future biomarker analysis)
Completed
- Multiple Sclerosis
- Blood draw for future biomarker analysis
-
Los Angeles, CaliforniaInvestigational Site Number 8400001
Mar 15, 2022
Multiple Sclerosis Trial in Stockholm (Temelimab 18 mg/kg, Temelimab 36mg/kg, Temelimab 54 mg/kg)
Terminated
- Multiple Sclerosis
- Temelimab 18 mg/kg
- +2 more
-
Stockholm, SwedenCenter for Neurology, Academic Specialist Center
Jul 4, 2022
Assess Adherence to Treatment for Patients With RMS (MAIN-MS)
Completed
- Relapsing Multiple Sclerosis (RMS)
- Rebif (Interferon beta-1a)
-
Alger, Algeria
- +40 more
Mar 22, 2022
Relapsing-remitting Multiple Sclerosis Trial in Rockland, Darmstadt (Evobrutinib, Avonex®, Avonex® matched Placebo)
Terminated
- Relapsing-remitting Multiple Sclerosis
- Evobrutinib
- +3 more
-
Rockland, Massachusetts
- +1 more
Jul 13, 2021
Relapsing Multiple Sclerosis (RMS) Trial in Germany, Poland (Cladribine, Placebo, Microgynon®)
Active, not recruiting
- Relapsing Multiple Sclerosis (RMS)
- Cladribine
- +2 more
-
Bochum, Germany
- +6 more
Feb 8, 2022
Postoperative Complications, Surgery Trial (Intraoperative ventilation with individualized high PEEP titrated to the lowest ?P
Not yet recruiting
- Postoperative Complications
- Surgery
- Intraoperative ventilation with individualized high PEEP titrated to the lowest ΔP with RMs
- (no location specified)
Oct 24, 2023
Multiple Sclerosis Trial in Stockholm (temelimab 18 mg/kg, temelimab 36 mg/kg, temelimab 54 mg/kg)
Completed
- Multiple Sclerosis
- temelimab 18 mg/kg
- +3 more
-
Stockholm, SwedenCenter for Neurology, Academic Specialist Center
Jul 4, 2022
Relapsing Forms of Multiple Sclerosis Trial in Australia, United States (EHP-101 25 mg OD, EHP-101 25 mg BID, EHP-101 50 mg OD)
Recruiting
- Relapsing Forms of Multiple Sclerosis
- EHP-101 25 mg OD
- +3 more
-
Cullman, Alabama
- +3 more
Apr 29, 2022
Coronary Artery Disease Trial in Switzerland (Magmaris Resorbable Magnesium Scaffold (RMS))
Terminated
- Coronary Artery Disease
- Magmaris Resorbable Magnesium Scaffold (RMS)
-
Genève, Switzerland
- +5 more
Jul 29, 2022
Relapsing Multiple Sclerosis (RMS) Trial in United States (Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate)
Recruiting
- Relapsing Multiple Sclerosis (RMS)
- Ofatumumab
- +2 more
-
Phoenix, Arizona
- +3 more
Jul 20, 2022
Relapsing Multiple Sclerosis Trial in Worldwide (Tolebrutinib, Teriflunomide HMR1726, Placebo to match Tolebrutinib)
Recruiting
- Relapsing Multiple Sclerosis
-
Beijin, ChinaPeking University Third Hospital
Jul 6, 2021
Complementary Feeding Trial in Ikeja, Kaduna (A&T IYCF intervention)
Completed
- Complementary Feeding
- A&T IYCF intervention
-
Ikeja, Lagos, Nigeria
- +1 more
Jan 13, 2021
Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia Trial (DREAMS 3G RMS, Xience DES)
Not yet recruiting
- Coronary Artery Disease
- +5 more
- DREAMS 3G RMS
- Xience DES
- (no location specified)
Sep 12, 2022